Clinical Trials Logo

Filter by:
NCT ID: NCT05312554 Withdrawn - Clinical trials for Patent Foramen Ovale

Safety and Efficacy of IrisFIT™ Patent Foramen Ovale Occluders

Start date: April 12, 2022
Phase: N/A
Study type: Interventional

To evaluate the performance of patent foramen ovale (PFO) device developed by Lifetech Technology (Shenzhen) Co., LTD

NCT ID: NCT05292443 Withdrawn - Clinical trials for Hepatocellular Carcinoma

Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver Cancer

Start date: December 20, 2021
Phase:
Study type: Observational [Patient Registry]

To evaluate the predictive value of ctDNA in response, relapse for liver cancer patients treated with immune checkpoint inhibitors

NCT ID: NCT05259813 Withdrawn - Clinical trials for Leukemia, Lymphocytic, Chronic, B-Cell

Phase I Study of JWCAR029 in Subjects With R/R CLL/SLL

Start date: February 28, 2022
Phase: Phase 1
Study type: Interventional

This is a Phase I, open-label, single-arm, single center study to assess the safety and efficacy of JWCAR029 in subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT ID: NCT05254236 Withdrawn - COVID-19 Clinical Trials

Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated Vaccine in Healthy Adults in in Hong Kong

Start date: February 10, 2022
Phase: Phase 2
Study type: Interventional

This is a randomized, double-blinded, Phase IIb clinical trial of COVID-19 vaccine (CoronaVac®) manufactured by Sinovac Research & Development Co., Ltd.The purpose of this study is to evaluate to evaluate the changes in immunogenicity before and after the booster vaccine using the high (1200 SU) or medium (600 SU) dose of COVID-19 Vaccine (Vero Cell), Inactivated.

NCT ID: NCT05252520 Withdrawn - Healthy Clinical Trials

A Study of JNJ-77474462 (Bermekimab) in Healthy Chinese Participants

Start date: May 1, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the pharmacokinetics (PK) of JNJ-77474462 following single ascending dose subcutaneous (SC) administration to healthy Chinese participants.

NCT ID: NCT05245916 Withdrawn - Clinical trials for Advanced Malignancies

IBI397 or Combination Therapies in Patients With Advanced Malignancies

Start date: April 14, 2022
Phase: Phase 1
Study type: Interventional

The primary objective of this phase Ia/Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of IBI397 or its Combination Therapies in Patients with Advanced Malignancies

NCT ID: NCT05212922 Withdrawn - HCC Clinical Trials

A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC

YH001
Start date: June 2023
Phase: Phase 2
Study type: Interventional

This is an Open-label, Non-Randomized, Multi-center Phase 2 study of YH001 in Combination with Toripalimab,The study is designed to determine the safety ,tolerability and antitumor activity of YH001 in combination with Toripalimab in subjects with advanced NSCLC and HCC.

NCT ID: NCT05180318 Withdrawn - Surgical Injury Clinical Trials

Prophylactic Effects of Esketamine in Surgical Patients

Start date: October 1, 2024
Phase: Phase 4
Study type: Interventional

Evidences have showing that esketamine has anti-inflammatory and therapeutic effects on depression and cardiac surgery. The investigators' preliminary results suggest that combined prophylactic and therapeutic use of esketamine could decrease the plasma levels of pro-inflammatory cytokines after LPS-induced endotoxemia. The investigators also found that combined prophylactic and therapeutic use of esketamine could attenuate systemic inflammation and inflammatory multi-organ injury in mice after CLP-induced lethal sepsis. Surgical trauma could elicit a marked inflammatory response with increased expression of pro-inflammatory cytokines, as well as postoperative immunosuppression. However, it remains unclear whether combined prophylactic and therapeutic use of esketamine could improve postoperative immunosuppression and alleviates systemic inflammatory response. This project aims to study whether combined prophylactic and therapeutic use of esketamine could improve the decreased number of lymphocyte subsets and increased plasma pro-inflammatory cytokines.

NCT ID: NCT05108363 Withdrawn - Cognitive Change Clinical Trials

Effect of Obstructive Sleep Apnea on Glucose Control and Cognitive Function

Start date: November 1, 2021
Phase: N/A
Study type: Interventional

Obstructive sleep apnea (OSA) may contribute to altered cognitive function in patients suffering from severe OSA. And lifestyle modification program may improve the cognitive function after 6 months of therapy.

NCT ID: NCT05099536 Withdrawn - Solid Tumor, Adult Clinical Trials

3D011-08 Monotherapy in Subjects With Advanced Solid Tumors

Start date: February 24, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is evaluate the the safety, tolerability, pharmacokinetics profiles, and preliminary efficacy of 3D011-08 in subjects with advanced solid tumors.